PBS Prescription Medicine Coverage Under OSHC: Annual Limits and Student Costs

International students arriving in Australia on a subclass 500 visa in 2025 face a prescription medicine landscape that has shifted in two important ways. The Pharmaceutical Benefits Scheme (PBS) patient co-payment was indexed on 1 January 2025, lifting the general patient contribution to $31.60 per script and the concessional co-payment to $7.70. For overseas students holding Overseas Student Health Cover (OSHC), the financial impact depends entirely on which insurer underwrites their policy and whether that policy includes PBS-subsidised prescription benefits at all. AHM and Medibank OSHC policies, for example, provide no PBS coverage whatsoever, while Allianz Care Australia, Bupa, and nib offer capped annual benefits that range from $150 to $500 per calendar year. The Department of Home Affairs requires OSHC for the duration of a student visa, but the minimum legislative standard set by the Health Insurance Act 1973 does not compel insurers to include pharmacy or PBS benefits. That gap means a student prescribed a common ongoing medication such as escitalopram or rosuvastatin can exhaust their annual OSHC pharmacy limit within the first three months of the year, then pay the full PBS co-payment or private prescription price out of pocket for the remaining nine months. This article examines the current PBS co-payment structure, maps each major OSHC insurer’s pharmacy benefit limits, and calculates the real out-of-pocket cost a student can expect for a chronic prescription in 2025.

The PBS Co-Payment Structure and OSHC Eligibility

How the PBS Patient Contribution Works in 2025

The PBS is a federal program administered by Services Australia that subsidises the cost of listed prescription medicines for Australian residents and eligible visitors. From 1 January 2025, the standard PBS patient co-payment for general patients is $31.60 per script. Concessional cardholders pay $7.70 per script (Services Australia, PBS Co-payment Rates, updated 1 January 2025). The Australian Government pays the balance above the co-payment up to the approved ex-manufacturer price for each PBS-listed item.

International students on a subclass 500 visa are not Australian residents for PBS purposes and do not hold a Medicare card. Their access to PBS-subsidised medicines depends solely on whether their OSHC insurer has negotiated a reciprocal or commercial arrangement that extends PBS pricing to OSHC members. The Department of Home Affairs subclass 500 visa conditions (Schedule 8, Condition 8501) mandate that the student “must maintain adequate arrangements for health insurance” but do not prescribe a minimum pharmaceutical benefit level (Department of Home Affairs, Student visa (subclass 500), accessed March 2025). The OSHC Deed, last updated 1 July 2023 and administered by the Department of Health and Aged Care, sets out minimum benefit requirements for hospital and medical services, yet pharmacy remains an ancillary benefit that insurers may offer or exclude at their discretion.

Which OSHC Insurers Provide PBS Coverage

Only three of the five major OSHC providers extend PBS-subsidised prescription benefits to their members: Allianz Care Australia, Bupa, and nib. AHM OSHC and Medibank Comprehensive OSHC policies explicitly exclude all pharmaceutical benefits, including PBS-listed medicines. The table below summarises the current pharmacy benefit limits as published on each insurer’s OSHC product disclosure statement or website as of March 2025.

The annual limit applies per calendar year, not per policy year. A student who activates a Bupa OSHC policy on 1 July 2025 receives the full $300 pharmacy limit for the remainder of 2025, and the limit resets on 1 January 2026 regardless of the policy renewal date. This calendar-year reset is consistent across Allianz, Bupa, and nib.

What the PBS Benefit Actually Pays For

For an OSHC member with PBS coverage, the insurer covers the PBS-subsidised cost above the $31.60 patient co-payment. If a medicine has a PBS-approved ex-manufacturer price of $70.00, the PBS subsidy is $38.40, and the insurer pays that $38.40. The student pays $31.60 at the pharmacy counter. The $31.60 counts toward the annual limit. Once the student’s cumulative PBS-subsidised amounts reach the annual cap, the insurer stops paying the subsidy, and the student must pay the full PBS co-payment—or the private prescription price if the medicine is dispensed privately—for all subsequent scripts that year.

A critical nuance: the annual limit applies to the PBS-subsidised portion, not the student’s out-of-pocket co-payment. A student filling twelve scripts per year at $31.60 each spends $379.20 out of pocket. With an Allianz $500 limit, the insurer covers the entire PBS subsidy for all twelve scripts. With a nib $150 limit, the insurer stops contributing after roughly five scripts, and the student pays the full $70.00 private price for the remaining seven scripts, adding $268.80 in unplanned costs.

Chronic Condition Cost Modelling: A Real-World Example

The Escitalopram Case Study

Escitalopram (brand name Lexapro) is a commonly prescribed selective serotonin reuptake inhibitor for depression and anxiety. Under the PBS, escitalopram 10 mg tablets are listed as a general benefit item. In March 2025, the PBS-approved price for a pack of 28 tablets is approximately $34.99, which sits just above the $31.60 general co-payment. The PBS subsidy per script is $3.39. The student pays $31.60 at the pharmacy.

A student prescribed one pack per month fills twelve scripts annually. The total PBS subsidy the insurer pays is 12 × $3.39 = $40.68. All three PBS-covering insurers would fully fund this medication for the entire year because the total subsidy falls well under even the lowest $150 nib limit. The student’s annual out-of-pocket cost is 12 × $31.60 = $379.20. This scenario is financially manageable under any OSHC policy with PBS coverage.

The Rosuvastatin Threshold Case

Rosuvastatin (brand name Crestor) 10 mg, a statin used for cholesterol management, has a higher PBS-approved price. As of March 2025, the approved ex-manufacturer price for a 30-tablet pack is approximately $45.72. The PBS subsidy is $14.12 per script. The student co-payment remains $31.60.

A student on rosuvastatin fills one script per month, twelve scripts per year. The annual PBS subsidy total is 12 × $14.12 = $169.44. Under an Allianz $500 policy, the insurer covers the full $169.44. Under Bupa’s $300 policy, the insurer covers the full $169.44. Under nib’s $150 policy, the insurer covers the first $150.00 of PBS subsidy, then the student becomes responsible for the remaining $19.44 in subsidy, plus the $31.60 co-payment, for the final scripts. The nib student pays an additional $19.44 beyond the standard $379.20 co-payment total, bringing the annual out-of-pocket to $398.64.

The nib limit breach occurs at script eleven. For scripts one through ten, the insurer pays $14.12 each ($141.20 cumulative). At script eleven, only $8.80 of subsidy remains. The insurer pays $8.80, and the student pays the remaining $5.32 of the PBS price, plus the $31.60 co-payment. Script twelve is fully unsubsidised: the student pays the full $45.72 private price. The total out-of-pocket for scripts eleven and twelve is $51.04, compared to $63.20 if fully covered.

The High-Cost Biologic Scenario

A small number of international students manage chronic autoimmune conditions requiring biologic medicines such as adalimumab (Humira). Under the PBS, adalimumab 40 mg injection has an approved price exceeding $1,200 per script. The PBS subsidy is approximately $1,168.40, and the patient co-payment is $31.60. A student requiring monthly adalimumab fills twelve scripts annually. The annual PBS subsidy is 12 × $1,168.40 = $14,020.80.

Under Allianz’s $500 limit, the insurer pays $500 toward the total PBS subsidy. The remaining $13,520.80 is the student’s responsibility. In practice, the student would exhaust the $500 limit on the first script. For the remaining eleven scripts, the pharmacy charges the full PBS co-payment of $31.60 plus the unsubsidised balance, or the medicine is dispensed privately at a cost that can exceed $1,200 per script. The student’s annual out-of-pocket cost exceeds $13,500. No OSHC policy on the Australian market adequately covers high-cost biologics. The privatehealth.gov.au website, managed by the Commonwealth Ombudsman, confirms that OSHC pharmacy benefits are “limited” and that “students with ongoing prescription needs should consider additional private health insurance or budget for significant out-of-pocket costs” (privatehealth.gov.au, Overseas Students Health Cover, updated 12 December 2024).

University OSHC Mandates and the Pharmacy Coverage Gap

How University Preferred Provider Arrangements Affect Choice

Many Australian universities maintain preferred-provider arrangements with specific OSHC insurers. The University of Melbourne, as of its 2025 international student enrolment guide, lists Bupa as its recommended OSHC provider and pre-loads Bupa OSHC into the student offer package. Monash University partners with Allianz Care Australia. The University of Sydney recommends Medibank. Students who accept the university’s default OSHC arrangement may not realise they have the right to switch insurers under the Private Health Insurance Act 2007 within the first 30 days of their policy, provided they have not made a claim.

A University of Sydney student defaulted into Medibank OSHC receives zero PBS prescription coverage. If that student develops a chronic condition requiring monthly medication, they face the full private prescription price from the first script. A University of Melbourne student on the Bupa default receives $300 in annual PBS coverage, which is adequate for low-cost medications but insufficient for mid-range or high-cost drugs. The university’s OSHC notice, typically embedded in the Confirmation of Enrolment (CoE) package, does not highlight the pharmacy benefit differential. The Department of Home Affairs subclass 500 visa grant notification letter states only that the student must maintain OSHC; it does not advise on pharmacy coverage adequacy.

The 30-Day Cooling-Off Switch Window

Under Australian private health insurance law, all OSHC policies carry a 30-day cooling-off period from the policy start date. A student who has not claimed can cancel the policy and purchase a different OSHC product. This window is the only no-penalty opportunity to switch from a non-PBS provider (AHM, Medibank) to a PBS-covering provider (Allianz, Bupa, nib). After 30 days, switching requires a new application and may involve waiting periods for pre-existing conditions, including a 12-month waiting period for psychiatric conditions and pre-existing ailments under most OSHC policies.

The practical challenge is timing. International students often arrive in Australia one to two weeks before orientation and spend the first month navigating accommodation, enrolment, and banking. The 30-day window can close before a student fills their first Australian prescription. Students managing pre-existing conditions should compare OSHC pharmacy benefits before departure and, if necessary, switch insurers immediately upon arrival.

How to Minimise Prescription Costs Under OSHC

Five Actionable Steps for Students

1. Check your OSHC pharmacy benefit before you fill a script. Log into your insurer’s member portal or call the overseas student helpline. Confirm the annual PBS limit, whether it applies per calendar year or policy year, and how much of the limit remains. Allianz, Bupa, and nib display this information in the member app.

2. Ask the pharmacist for the PBS price, not the private price. When presenting an OSHC membership card at a pharmacy that accepts PBS billing for OSHC members, the pharmacist must process the script through the PBS claims system. If the pharmacist says the medicine is not covered, ask them to confirm that they have selected the OSHC insurer in the PBS online claiming system. Some community pharmacies are unfamiliar with OSHC PBS processing and default to private pricing.

3. Switch insurers within the 30-day cooling-off period if your current policy excludes PBS. A student on AHM or Medibank OSHC who has not claimed can cancel and purchase Allianz, Bupa, or nib OSHC. Compare the monthly premium difference against the expected annual prescription cost. As of March 2025, Allianz Care Australia single OSHC starts at $61.75 per month, Bupa at $59.50 per month, nib at $56.00 per month, and AHM at $54.95 per month. The premium differential between AHM and Bupa is $4.55 per month, or $54.60 per year, which is less than the cost of two PBS co-payments.

4. Request a 90-day or authority script for chronic medications. Under the PBS Continued Dispensing arrangements, a general practitioner can prescribe up to a 90-day supply for a stable chronic condition. A single 90-day script attracts one $31.60 co-payment instead of three. This reduces the number of annual scripts from twelve to four, which keeps total PBS subsidy well within even the lowest $150 nib limit for most common medications.

5. Budget for the PBS Safety Net gap. The PBS Safety Net, which reduces the co-payment to $7.70 for general patients once an annual threshold of $1,647.90 in out-of-pocket costs is reached (Services Australia, PBS Safety Net Thresholds, updated 1 January 2025), does not apply to OSHC members because they are not Medicare cardholders. OSHC members have no safety net protection. Every script beyond the insurer’s annual limit is paid in full. Students on high-cost medications should treat the insurer’s annual pharmacy limit as a hard cap and budget the remaining months at the full private prescription price.